TAMPA, Fla. and LONDON, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today ...
Pancreatic cancer is one of the deadliest diseases known to medicine. It’s hard to detect, quick to spread, and resistant to most treatments. With a five-year survival rate of just 13%, pancreatic ...
Akari Therapeutics plc has released new preclinical data indicating the therapeutic potential of AKTX-101 in pancreatic cancer driven by KRAS mutations. AKTX-101 is an antibody-drug conjugate (ADC) ...
Pancreatic cancer has a five-year survival rate of just 13%, making it the deadliest cancer, according to the American Cancer Society. It typically causes no symptoms until it has already metastasized ...
TEL AVIV, Israel, May 30, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare disease, today ...
RVMD stays a Strong Buy as RAS inhibitor trials advance; phase 3 RASolute-302 is a key 2026 catalyst. Read the latest ...
Data highlights the ability of Akari’s Trop2 ADC, AKTX-101, to kill K-Ras G12V mutated cancer cell lines in preclinical models, potentially addressing one of the most lethal cancers with the lowest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback